How to use neuroimaging biomarkers in the diagnosis framework of neurodegenerative diseases?

Neuroimaging biomarkers, together with CSF biomarkers, are more and more used to support the early and differential clinical diagnosis of neurodegenerative diseases in clinical setting that have access to those techniques. Based on a consensus of multidisciplinary experts leading to a princeps publi...

Full description

Saved in:
Bibliographic Details
Published inRevue neurologique Vol. 178; no. 5; pp. 490 - 497
Main Author Chételat, G.
Format Journal Article
LanguageEnglish
Published France Elsevier Masson SAS 01.05.2022
Elsevier Masson
Subjects
Alzheimer's disease
Cognitive science
Differential diagnosis
Early diagnosis
Neurodegenerative diseases
Neuroimaging biomarkers
Neuroscience
Early diagnosis
Differential diagnosis
Neurodegenerative diseases
Alzheimer's disease
Neuroimaging biomarkers
early diagnosis
neurodegenerative diseases
differential diagnosis
neuroimaging biomarkers
Online AccessGet full text

Cover

More Information
Summary:Neuroimaging biomarkers, together with CSF biomarkers, are more and more used to support the early and differential clinical diagnosis of neurodegenerative diseases in clinical setting that have access to those techniques. Based on a consensus of multidisciplinary experts leading to a princeps publication in the Lancet Neurology [Chételat et al., Lancet Neurol 2020; 19: 951–62], we proposed a three-arm diagnosis algorithm detailing the optimal combination of biomarkers for the diagnosis of neurodegenerative diseases according to the clinical presentation. The main conclusions of this princeps article are summarized here, including a brief overview of the complementarity of the most validated neuroimaging biomarkers available, and an argued presentation of the proposed diagnosis algorithm.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0035-3787
DOI:10.1016/j.neurol.2022.03.006